The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed to the regulator's request to temporarily suspend shipments of the Duchenne muscular dystrophy (DMD) gene therapy.

Sarepta Therapeutics Inc. shares soared after the company said it was cutting more than a third of its workforce and that its gene therapy for a fatal muscle disorder would stay on the market with warnings about the potential for liver failure.